ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.742,55
-0,05%
Dow Jones
42.392,46
0,52%
Euro vs US Dollar
1,11609
-0,14%
Bitcoin
65.837,68
1,00%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Immuron Ltd (IMRN)

  7. Immuron Ltd (IMRN) News

IMRN

Immuron (IMRN)

Immuron Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IMRN
DatumZeitQuelleÜberschriftSymbolFirma
26/09/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
09/09/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
05/09/202417h54GlobeNewswire Inc.Immuron Plans Phase 2 Trial for IMM-529 following FDA reviewNASDAQ:IMRNImmuron Ltd
05/09/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
21/08/202415h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
16/08/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
16/08/202412h00GlobeNewswire Inc.Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®NASDAQ:IMRNImmuron Ltd
07/08/202412h26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
07/08/202412h00GlobeNewswire Inc.Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct ConnectNASDAQ:IMRNImmuron Ltd
22/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMRNImmuron Ltd
18/07/202412h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
15/07/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
15/07/202414h00GlobeNewswire Inc.Immuron announces record Travelan® sales globally, Australia and USANASDAQ:IMRNImmuron Ltd
09/07/202412h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
02/07/202412h00GlobeNewswire Inc.Immuron requests pre-IND meeting for IMM-529 with FDA filingNASDAQ:IMRNImmuron Ltd
05/06/202412h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
31/05/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
31/05/202412h00GlobeNewswire Inc.Immuron CEO Steven Lydeamore to present at Peak Sky HighNASDAQ:IMRNImmuron Ltd
31/05/202412h00GlobeNewswire Inc.Immuron Board ChangesNASDAQ:IMRNImmuron Ltd
03/05/202412h00GlobeNewswire Inc.Immuron Director ResignationNASDAQ:IMRNImmuron Ltd
15/04/202412h00GlobeNewswire Inc.Immuron to host Live Virtual EventNASDAQ:IMRNImmuron Ltd
10/04/202412h00GlobeNewswire Inc.Immuron Travelan® sales continued strong growthNASDAQ:IMRNImmuron Ltd
07/03/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
07/03/202412h00GlobeNewswire Inc.Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the USNASDAQ:IMRNImmuron Ltd
28/02/202414h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
21/02/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
21/02/202412h00GlobeNewswire Inc.Immuron Presentation Australian Biologics Festival 2024NASDAQ:IMRNImmuron Ltd
13/02/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMRNImmuron Ltd
13/02/202412h00GlobeNewswire Inc.Immuron achieves record Travelan® salesNASDAQ:IMRNImmuron Ltd
08/02/202412h00GlobeNewswire Inc.Immuron CEO, Steven Lydeamore Investor Webinar PresentationNASDAQ:IMRNImmuron Ltd
 Showing the most relevant articles for your search:NASDAQ:IMRN

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
TG
BAYN
Bayer
TG
LHA
Deutsche Lufthansa
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
CCOM
SILVER
SILVER
TG
DBK
Deutsche Bank
COIN
AVAXUSD
Avalanche
USOTC
BASFY
BASF (QX)
TG
TUI1
Tui
DBI
SDXP
SDAX
NYSE
MCD
McDonalds
TG
NOV
Novo Nordisk
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten